Stefano Pravato

467 total citations
19 papers, 203 citations indexed

About

Stefano Pravato is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Stefano Pravato has authored 19 papers receiving a total of 203 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Genetics, 9 papers in Pathology and Forensic Medicine and 7 papers in Immunology. Recurrent topics in Stefano Pravato's work include Chronic Lymphocytic Leukemia Research (12 papers), Lymphoma Diagnosis and Treatment (7 papers) and Immunodeficiency and Autoimmune Disorders (5 papers). Stefano Pravato is often cited by papers focused on Chronic Lymphocytic Leukemia Research (12 papers), Lymphoma Diagnosis and Treatment (7 papers) and Immunodeficiency and Autoimmune Disorders (5 papers). Stefano Pravato collaborates with scholars based in Italy and United States. Stefano Pravato's co-authors include Livio Trentin, Andrea Visentin, Monica Facco, Francesco Piazza, Federica Frezzato, Gianpietro Semenzato, Silvia Imbergamo, Paolo Gallo, Davide Poggiali and Filippo Severin and has published in prestigious journals such as Blood, PLoS ONE and British Journal of Haematology.

In The Last Decade

Stefano Pravato

18 papers receiving 201 citations

Peers

Stefano Pravato
Stefano Pravato
Citations per year, relative to Stefano Pravato Stefano Pravato (= 1×) peers Karolina Piasecka‐Stryczynska

Countries citing papers authored by Stefano Pravato

Since Specialization
Citations

This map shows the geographic impact of Stefano Pravato's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stefano Pravato with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stefano Pravato more than expected).

Fields of papers citing papers by Stefano Pravato

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stefano Pravato. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stefano Pravato. The network helps show where Stefano Pravato may publish in the future.

Co-authorship network of co-authors of Stefano Pravato

This figure shows the co-authorship network connecting the top 25 collaborators of Stefano Pravato. A scholar is included among the top collaborators of Stefano Pravato based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stefano Pravato. Stefano Pravato is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Frezzato, Federica, Laura Bonaldi, Stefano Pravato, et al.. (2024). Exploring the prognostic role of complex karyotype in chronic lymphocytic leukaemia patients treated with venetoclax‐based regimens. British Journal of Haematology. 205(1). 189–193. 1 indexed citations
2.
Pravato, Stefano, Elisa Pagnin, Laura Bonaldi, et al.. (2024). Chronic Lymphocytic Leukemia (CLL) with Borderline Immunoglobulin Heavy Chain Mutational Status, a Rare Subgroup of CLL with Variable Disease Course. Cancers. 16(6). 1095–1095. 3 indexed citations
3.
Lessi, Federica, Matteo Leoncin, Carla Filì, et al.. (2024). Efficacy and safety of venetoclax plus hypomethylating agents in relapsed/refractory acute myeloid leukemia: a multicenter real-life experience. Frontiers in Oncology. 14. 1370405–1370405. 4 indexed citations
4.
Tanasi, Ilaria, Antonella Bruzzese, Ambra Di Veroli, et al.. (2024). Association of Glasdegib + Low-Dose Cytarabine (AraC)) in the Real-Life Treatment of Very Frail Elderly Acute Myeloid Leukemias (AML) Patients. Blood. 144(Supplement 1). 6041–6041. 1 indexed citations
5.
Severin, Filippo, Andrea Visentin, Elisa Pagnin, et al.. (2023). Focal adhesion kinase activation by calcium‐dependent calpain is involved in chronic lymphocytic leukaemia cell aggressiveness. British Journal of Haematology. 203(2). 224–236. 5 indexed citations
6.
Gregianin, Michele, Stefania Vio, Federica Vianello, et al.. (2023). P1075: ADVANCED-STAGE CHL INTERNATIONAL PROGNOSTICATION INDEX: EXTERNAL VALIDATION IN A SINGLE-CENTER RETROSPECTIVE PATIENT DATASET AND COMPARISON TO THE HASENCLEVER IPS. HemaSphere. 7(S3). e132523d–e132523d. 2 indexed citations
7.
Visentin, Andrea, Stefano Pravato, Silvia Imbergamo, et al.. (2022). A Retrospective Study on the Efficacy of Subcutaneous Immunoglobulin as Compared to Intravenous Formulation in Patients with Chronic Lymphocytic Leukemia and Secondary Antibody Deficiency. Current Oncology. 30(1). 274–283. 9 indexed citations
8.
Bellis, Eleonora De, Silvia Imbergamo, Anna Candoni, et al.. (2022). Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience. Leukemia Research. 114. 106803–106803. 15 indexed citations
10.
Visentin, Andrea, Stefano Pravato, Francesca Castellani, et al.. (2022). From Biology to Treatment of Monoclonal Gammopathies of Neurological Significance. Cancers. 14(6). 1562–1562. 10 indexed citations
11.
Frezzato, Federica, Andrea Visentin, Filippo Severin, et al.. (2021). Targeting of HSP70/HSF1 Axis Abrogates In Vitro Ibrutinib-Resistance in Chronic Lymphocytic Leukemia. Cancers. 13(21). 5453–5453. 6 indexed citations
12.
Visentin, Andrea, Laura Bonaldi, Gian Matteo Rigolin, et al.. (2021). The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation. Haematologica. 107(4). 868–876. 31 indexed citations
13.
Visentin, Andrea, Silvia Imbergamo, Valentina Trimarco, et al.. (2020). Ibrutinib in relapsed hairy cell leukemia variant: A case report and review of the literature. Hematological Oncology. 38(5). 823–826. 15 indexed citations
14.
Visentin, Andrea, Federica Frezzato, Filippo Severin, et al.. (2020). <p>Lights and Shade of Next-Generation Pi3k Inhibitors in Chronic Lymphocytic Leukemia</p>. OncoTargets and Therapy. Volume 13. 9679–9688. 19 indexed citations
15.
Visentin, Andrea, Gian Matteo Rigolin, Francesca Romana Mauro, et al.. (2020). Complex Karyotype Subtypes at Chronic Lymphocytic Leukemia Diagnosis Refine the Risk of Developing a Richter Syndrome. the Richter Syndrome Scoring System. Blood. 136(Supplement 1). 33–34. 1 indexed citations
16.
Visentin, Andrea, Monica Facco, Carmela Gurrieri, et al.. (2019). Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments. Clinical Lymphoma Myeloma & Leukemia. 19(10). 678–685.e4. 22 indexed citations
17.
Visentin, Andrea, Francesca Romana Mauro, Silvia Imbergamo, et al.. (2018). Protective Role Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia: FOCUS on Subcutaneous Immunoglobulin Formulations. Blood. 132(Supplement 1). 4954–4954. 2 indexed citations
18.
Puthenparampil, Marco, Lisa Federle, Silvia Miante, et al.. (2017). BAFF Index and CXCL13 levels in the cerebrospinal fluid associate respectively with intrathecal IgG synthesis and cortical atrophy in multiple sclerosis at clinical onset. Journal of Neuroinflammation. 14(1). 11–11. 34 indexed citations
19.
Favaretto, Alice, Andrea Lazzarotto, Stefano Pravato, et al.. (2017). Enlarged Virchow Robin spaces associate with cognitive decline in multiple sclerosis. PLoS ONE. 12(10). e0185626–e0185626. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026